Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

regeneron headquarters

UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

CHMP has now adopted a positive opinion for the treatment

- PMLiVE

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

Bedrock Healthcare

Bedrock’s strong start to 2021

Just two months into the year and at Bedrock we’ve already added FOUR new people to an ever-growing team!

Bedrock Healthcare Communications

Enabling Patient-Focused Research Through Virtual Clinical Trials

Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital...

Impetus Digital

Innovative Approaches to Managing Mental Health Conditions

Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and...

Impetus Digital

Newcells Biotech secures over £5m for 3D tissue models

Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models

Onyx Health

- PMLiVE

UK introduces Rare Diseases Framework to improve the lives of people with rare diseases

bluebird bio releases a video to raise awareness – Rare Disease Day 2021 is on 28 February

- PMLiVE

FDA briefing document backs J&J’s one-dose COVID-19 vaccine

Company is seeking an emergency use authorisation in the US

- PMLiVE

Moderna announces plans for COVID-19 variant-specific booster jabs and new production targets

Company is developing variant-specific COVID-19 vaccine candidate

- PMLiVE

Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds

Study included around 1.2 million people in Israel

- PMLiVE

Communiqué Awards 2021 entry deadline is two weeks away!

The deadline is 11 March – make sure you start working on your entries now

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links